Compass Pathways Accelerates Psilocybin Launch Timeline by 9-12 Months Post published:November 4, 2025 Post category:Analysis/News/Pα+
Pα+ Psychedelic Bulletin #212: Delix Posts Early Efficacy Signal; NRx Wants FDA to Ban Competitors’ Ketamine; Cybin Raises $175M Post published:October 31, 2025 Post category:Psychedelic Bulletin/Pα+
Pα+ Psychedelic Bulletin #211: AbbVie Officially Enters Psychedelics; atai-Beckley’s 5-MeO-DMT Scores Breakthrough Therapy Designation; California Bill Signed Post published:October 24, 2025 Post category:Psychedelic Bulletin/Pα+
Q3’25 Investor Survey: What are Investors Most Concerned About? Post published:October 23, 2025 Post category:Analysis/News/Pα+
Q3’25 Survey: What are Psychedelics Investors Excited About? Post published:October 21, 2025 Post category:Analysis/News/Pα+
September 2025 Psychedelic Patent Update Post published:October 20, 2025 Post category:Psychedelic Patent Analysis/Pα+
Recovered or Reimagined? Samuli Kangaslampi on Psychedelics and Autobiographical Recall Post published:October 14, 2025 Post category:Interviews/Pα+
Q2 2025: Oregon Psilocybin Services Update Post published:October 10, 2025 Post category:Analysis/News/Pα+